Skip to main content
Premium Trial:

Request an Annual Quote

ArcherDX's FusionPlex Blood Cancer Panels

ArcherDX has launched the Archer FusionPlex Blood Cancer panels, three new targeted next-generation sequencing assays to capture and identify known and novel gene fusions, point mutations, and relative expression levels in myeloid and lymphoid origin malignancies. The panels utilize Archer's proprietary Anchored Multiplex PCR to detect known and novel fusions from RNA, and it also tags each input fragment with a barcode for molecular quantification for expression level detection and added confidence in mutation detection. Each new panel interrogate 80-90 genes, simultaneously detecting fusions, critical point mutations, and expression levels when analyzed using the Archer Analysis bioinformatics platform, the company said.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.